On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – ...

Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, announced completion of a ...

NYSE:ANRO) Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

BrainSight AI raised $5 million in pre-series A funding round. With plans to expand in India and pursue FDA certification.

Geode Capital Management LLC grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 148.7% in ...

Patient Enrollment Ongoing in Phase 2 RECONNECT Trial of RE104 in Postpartum Depression (PPD); Topline Data Anticipated Mid-2025Initiation of ...

Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego -based GMP facility.

Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.